

August 2012 ♦ Produced by The Prescribing Team

## NHSGGC Prescribing Indicators 2012/2013 Update

This bulletin provides an update to the prescribing indicator information included in the [April/May 2012](#) edition. Baseline data is now available for the new National Therapeutic Indicators (NTIs) and their details have been finalised.

Last year's Quality Programme (QP) Prescribing Indicators encouraged an evaluation of prescribing across Scotland. With the removal of the prescribing component of QP the SGHD were keen to continue having a national focus on prescribing and have developed National Therapeutic Indicators (NTIs). This Scottish Quality Prescribing Initiative (PCA(M)(2012)08) will compliment the existing QOF indicators relating to prescribing actions (MED 6 & 10) and encourage practices to implement prescribing change in up to 2 areas.

The Rational Prescribing Indicator (RPI) scheme remains with funding by NHSGGC for the additional work the same as last year. The aim is to promote quality and cost effective improvements in prescribing.

The table below shows the baseline data period and the final data period for measuring the changes for each of the indicator types:

Indicator Type	Baseline Period	Final Measurement Period
RPI	Oct-Dec 2011	Oct-Dec 2012
GMS MED 6 & 10	Oct-Dec 2011	Jan-Mar 2013
NTI	Jan-Mar 2012	Jan-Mar 2013

The indicators for the financial year 2012/2013 are as follows:

Type	Indicator & Measure	Target	Target Shift
<b>GASTROINTESTINAL</b>			
NTI	Proton pump inhibitors (DDDs per 1000 patients per day)	89.44	7.62 ▼
RPI	Proton pump inhibitors (DDDs per 1000 weighted patients per day)	98.67	5.14 ▼
NTI	High strength oral PPIs as a percentage of all oral PPIs (DDDs)	2.59%	0.87% ▼
GMS	High strength oral PPIs as a percentage of all oral PPIs (DDDs)	3.24%	0.77% ▼
GMS	Generic lansoprazole and omeprazole capsules as a percentage of all single agent oral PPIs (Items)	94.18%	0.75% ▲

GMS	Omeprazole capsules as a percentage of all omeprazole (excluding MUPS®) (DDD <sub>s</sub> )	99.79%	0.17% ▲
GMS	Gaviscon® Advance 500ml to Peptac® 500ml (Quantity)	80% switch	n/a
GMS	Movicol® (excluding paediatric) to Laxido® (Quantity)	80% switch	n/a
GMS	Cimetidine 400mg & 800mg tabs to ranitidine 150mg & 300mg tabs (Quantity)	100% switch	n/a
<b>CARDIOVASCULAR</b>			
NTI	Simvastatin, atorvastatin and pravastatin as a percentage of all statins (DDD <sub>s</sub> )	98.21%	0.99% ▲
RPI	Simvastatin, atorvastatin and pravastatin as a percentage of all statins (DDD <sub>s</sub> )	99.12%	0.42% ▲
RPI	Generic amlodipine maleate/mesilate as a percentage of all prescribing of amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine and nisoldipine (ie dihydropyridine calcium-channel blockers) (Items)	87.58%	2.08% ▲
GMS	Generic doxazosin standard release tablets as a percentage of all doxazosin (Items)	97.12%	3.58% ▲
RPI	Generic ISMN standard release tablets as a percentage of all ISMN (Items)	87.30%	3.22% ▲
NTI	Dipyridamole MR 200mg (DDD <sub>s</sub> per 1000 patients per day)	2.45	0.46 ▼
RPI	Dipyridamole MR 200mg (DDD <sub>s</sub> per 1000 weighted patients per day)	2.39	0.45 ▼
RPI	Omega-3-acid ethyl esters (Quantity per 1000 weighted patients per day)	0.12	0.28 ▼
NTI	Ezetimibe, including combinations, as a percentage of all ezetimibe, including combinations, and statins (DDD <sub>s</sub> )	0.45%	0.32% ▼
RPI/GMS	Ezetimibe, including combinations, as a percentage of all ezetimibe, including combinations, and statins (DDD <sub>s</sub> )	0.48%	0.22% ▼
RPI	Ezetimibe (including combinations) (DDD <sub>s</sub> per 1000 weighted patients per day)	0.74	0.29 ▼
GMS	Ramipril tabs to ramipril caps (Quantity)	100% switch	n/a
<b>RESPIRATORY</b>			
NTI	High strength steroid inhalers as a percentage of all inhalers in BNF Sections 3.1 and 3.2 (Items)	12.34%	1.25% ▼
GMS	High strength steroid inhalers as a percentage of all inhalers in BNF Sections 3.1 and 3.2 (Items)	11.03%	1.05% ▼
GMS	Leukotriene receptor antagonists (Items per 1000 patients)	4.67	1.05 ▼
GMS	Mucolytics (Items per 1000 weighted patients)	4.29	1.24 ▼
<b>CNS (PSYCHOTROPICS)</b>			
NTI	Hypnotics and anxiolytics (BNF 4.1.1 and 4.1.2) (DDD <sub>s</sub> per 1000 patients per day)	12.87	2.91 ▼
GMS	Hypnotics and anxiolytics (BNF 4.1.1 and 4.1.2) (DDD <sub>s</sub> per 1000 weighted patients per day)	14.43	3.89 ▼
GMS	Buspirone (Cost per 1000 weighted patients per day)	£0.00	£0.10 ▼

GMS	Fluoxetine, citalopram and sertraline as a percentage of all SSRIs, duloxetine, mirtazapine, reboxetine and venlafaxine (Items)	75.16%	1.50% ▲
RPI	Escitalopram as a percentage of all SSRIs (Items)	1.04%	0.41% ▼
RPI	Generic standard release venlafaxine as a percentage of all solid dose venlafaxine (Items)	49.21%	5.25% ▲
GMS	Review of antidepressants - percentage of those on repeat prescription for antidepressants who have had a medication review in the last 2 years	n/a	n/a
RPI	Quetiapine MR as a percentage of all quetiapine (Items)	8.06%	5.66% ▼
GMS	Lormetazepam or 1mg loprazolam to zopiclone (Quantity)	60% switch	n/a
GMS	Amisulpride 400mg tabs to 2 x amisulpride 200mg tabs (Quantity)	50% switch	n/a
GMS	Fluoxetine 60mg caps to 3 x fluoxetine 20mg caps (Quantity)	100% switch	n/a
<b>CNS (PAIN)</b>			
GMS	Opioids (BNF 4.7.2, co-codamol 30/500, co-dydramol 20/500 and 30/500, and Tramacet®) (Items per 1000 weighted patients per day)	1.60	0.18 ▼
GMS	Oxycodone and morphine (DDD per 1000 weighted patients per day)	1.58	0.39 ▼
GMS	Oxycodone as a percentage of all oxycodone and morphine (DDDs)	21.99%	5.93% ▼
GMS	Tramadol (and combinations) (DDD per 1000 weighted patients per day)	7.5	0.98 ▼
GMS	Fentanyl (excluding injections) (DDD per 1000 weighted patients per day)	0.15	0.21 ▼
GMS	Buprenorphine patches (DDD per 1000 weighted patients per day)	0.11	0.08 ▼
GMS	Lidocaine patches (Items per 1000 weighted patients per day)	0.2	0.29 ▼
RPI	Pregabalin and gabapentin (Cost per 1000 weighted patients per day)	£7.51	£1.17 ▼
GMS	Oral triptans (DDD per 1000 weighted patients per day)	0.51	0.13 ▼
GMS	Gabapentin 600mg and 800mg tabs to 2 x 300mg and 2 x 400mg gabapentin caps (Quantity)	90% switch	n/a
GMS	Propranolol 80mg and 160mg modified-release caps to propranolol 40mg and 80mg standard release tabs (Quantity)	80% switch	n/a
<b>ANTI-INFECTIVES</b>			
NTI	Antibacterial drugs (Items per 1000 patients per day)	1.82	0.13 ▼
GMS	Antibacterial drugs (Items per 1000 patients per day)	1.82	0.13 ▼
GMS	Quinolones (DDD per 1000 patients per day)	0.42	0.11 ▼
NTI	4C antibacterial drugs (Items per 1000 patients per day)	0.13	0.02 ▼
GMS	4C antibacterial drugs (Items per 1000 patients per 100 days)	14.11	2.34 ▼

<b>DIABETES</b>			
NTI	Metformin and sulphonylureas as a percentage of all antidiabetic drugs (BNF 6.1.2) (DDDs)	91.14%	1.49% ▲
GMS	Metformin and sulphonylureas as a percentage of all antidiabetic drugs (BNF 6.1.2) (DDDs)	91.06%	1.37% ▲
GMS	Long-acting insulin analogues (detemir and glargine) as a percentage of all intermediate and long-acting insulins (excluding biphasic insulins) (DDDs)	48.23%	4.07% ▼
GMS	Exenatide as a percentage of all glucagon-like peptide-1 prescribing (DDDs)	47.06%	9.41% ▲
GMS	Glucagon-like peptide-1 (DDDs per 1000 weighted patients per day)	0.62	0.20 ▼
GMS	Metformin solution 100ml to 20 x metformin 500mg tablets (reduction in metformin solution) (Quantity)	100% reduction	n/a
GMS	Med Level 1 review of consumables prescribed for the management of diabetes	n/a	n/a
<b>UROLOGY</b>			
RPI	Generic finasteride as a percentage of all prescribing of finasteride and dutasteride (including combinations) (Items)	90.91%	3.29% ▲
GMS	Antimuscarinics (BNF 7.4.2) (DDDs per 1000 weighted patients per day)	7.96	0.76 ▼
<b>MUSCULOSKELETAL, ANTI-INFLAMMATORIES &amp; OSTEOPOROSIS</b>			
RPI	Cox-2s as a percentage of all oral NSAIDs including Cox-2s (Items)	2.09%	0.82% ▼
GMS	NSAIDs (all oral and injectable NSAIDs including Cox-2s) (DDDs per 1000 weighted patients)	31.8	3.36 ▼
GMS	Generic Formulary recommended NSAID gel as a percentage of all topical NSAIDs (Items)	85.93%	7.53% ▲
NTI	Quinine (DDDs per 1000 patients per day)	0.75	0.16 ▼
RPI	Quinine (DDDs per 1000 weighted patients per day)	0.74	0.15 ▼
<b>NUTRITION AND BLOOD</b>			
GMS	Sip feeds (Quantity per 1000 weighted patients per day)	2.33	0.38 ▼
GMS	Orlistat (DDDs per 1000 weighted patients per day)	0.41	0.17 ▼
<b>SKIN AND WOUNDS</b>			
GMS	Formulary wound dressing products as a percentage of all wound dressing products (Items)	83.40%	2.94% ▲
NTI	Antimicrobial wound dressing products as a percentage of all wound dressing products (Items)	11.14%	1.77% ▼
GMS	Antimicrobial wound dressing products as a percentage of all wound dressing products (Items)	12.66%	1.61% ▼
GMS	Foam wound dressing products as a percentage of all wound dressing products (Items)	10.13%	1.97% ▼
<b>ENT</b>			
GMS	Preferred list drugs used in nasal allergy (beclometasone dipropionate and budesonide (Rhinocort Aqua®)) as a percentage of all drugs used in nasal allergy (BNF 12.2.1) (Items)	51.24%	5.01% ▲

Please note there are now separate targets/target shifts for indicators which have been selected as NTIs and RPI/GMS indicators by practices.